Olivier Boutaud

Recent research from the Warren Center for Neuroscience Drug Discovery, published in the Journal of Medicinal Chemistry, resulted in the proposal of a novel target and mechanism for improving cognition—a negative symptom—while also treating positive symptoms of the disease. Read More

We often think about diseases in terms of the symptoms they present. A cold might give you the sniffles or even GI distress, while malaria can give you fever, chills, or nausea... Read More

Researchers at the Warren Center for Neuroscience Drug Discovery, a clinical stage biotech within the Vanderbilt University School of Medicine Basic Sciences, have detailed the successful drug discovery of a Phase I Single Ascending Dose clinical trial of VU319, a drug for memory loss in people with Alzheimer’s disease and schizophrenia. Read More

In just over two years, a Vanderbilt-Neumora collaboration has led to the Phase 1 clinical trial of a treatment for schizophrenia spectrum disorders, which affect 3.7 million adults in the United States. This is the third chemical compound discovered at the Warren Center for Neuroscience Drug Discovery to reach Phase 1 clinical trials.     Read More

Vanderbilt investigators have identified a new biomarker to assess platelet function. Read More